Publication | Closed Access

Rosuvastatin (20, 40 and 80 MG) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 MG) in patients with heterozygous familial hypercholesterolaemia

Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolCardiovascular DiseasePharmacologyHyperlipidemiaTreatment GoalsMedicineAtherosclerosisDyslipidemiaOxidative Stress